Paper by RAS Academician A. I. Archakov, Doctor of Science (Biology) O. M. Ipatova,
RAS Corresponding Member A. V. Lisitsa, and Doctor of Science (Biology) S. A. Moshkovskii*
Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia
e-mail: inst@ibmc.msk.ru
Received December 23, 2015
Abstract—Today, requirements on the safety and effectiveness of medications are growing worldwide, leading
to increased costs of their development. However, this paper shows that xenobiotic preparations cannot but
cause side effects; the growing number of preparations in the market, polypharmacy abuse, and self-treatment
increase the number of adverse consequences, including fatal ones. Health hazards also lurk in interactions
between drugs and dietary supplements because of the latter’s lower certification level, as well as in their treat-
ment effects associated with the patient’s diet and lifestyle specifics. In order to avoid negative consequences
of drug intake, it is necessary to develop a personalized approach to xenobiotic pharmacotherapy that would
use the results of pharmacogenomics and pharmacometabolomics, as well as therapeutic drug monitoring with
strict account for possible drug–drug interactions.
Keywords: drug, personalized medicine, pharmacogenomics, therapeutic drug monitoring, polypharmacy,
drug–drug interaction.
DOI: 10.1134/S1019331616030138
Pleiades Publishing home page | journal home page | top
If you have any problems with this server, contact webmaster.